Vyas Tungaturti is a seasoned M&A operator and advisor specializing in large-scale mergers, acquisitions, and private equity due diligence. His experience spans integration and divestiture office leadership, complex cross-border transactions, and the application of AI and machine learning to deal execution. Founder of CorpDev.Org and builder of Kai, an AI due-diligence platform for deal teams, Vyas writes on deal intelligence, value creation, and how AI is reshaping M&A and PE workflows.
As global markets reel from President Donald Trump's escalating trade wars, investment bankers and corporate dealmakers are engineering unprecedented financial structures to keep mergers and...
As global markets grapple with tariff uncertainties and shifting monetary policies, Blackstone Inc. (NYSE: BX) has demonstrated remarkable resilience, reporting first-quarter distributable earnings...
As SolarWinds navigates its pending $4.4 billion acquisition by Turn/River Capital, new legal challenges and regulatory scrutiny reveal the complex interplay between cybersecurity governance, public...
In a bold move consolidating its leadership in direct air capture (DAC) technology, Occidental Petroleum subsidiary Oxy Low Carbon Ventures acquired carbon removal startup Holocene Climate...
In a landmark $24.25 billion transaction announced April 17, 2025, Global Payments (NYSE: GPN) has positioned itself as the world's largest pure-play merchant acquirer through its acquisition of...
As Meta's landmark antitrust trial enters its second week, newly revealed court documents and testimony from CEO Mark Zuckerberg have exposed the social media giant's decade-long pattern of...
In a move signaling deeper consolidation within the global payments sector, Barclays PLC and Brookfield Asset Management have finalized a multi-phase partnership to transform the British bank's...
New research led by Dr. Busra Agcayazi at Howard University reveals a compelling correlation between CEO international backgrounds and superior cross-border merger outcomes. Analyzing 37,000 M&A...
The pharmaceutical and biotechnology sectors face unprecedented disruption as President Trump's proposed 10-25% tariffs on imported drugs and medical devices threaten to upend global supply chains,...
In a landmark transaction underscoring private equity's growing appetite for European digital infrastructure assets, Kohlberg Kravis Roberts & Co. (KKR) announced on April 16, 2025, its €450...
